Decode Will Focus on Dx Sales in 2008; Targeted Drugs on the Distant Horizon | GenomeWeb
Decode Genetics this year plans to encourage greater adoption of its suite of diagnostics that gauge patients’ risk of developing common diseases, according to CEO Kari Stefansson.
He said these tests, which will be marketed directly to consumers, will bring financial returns in the short term, while several genetically targeted drugs in its pipeline will foment long-term growth.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.